倍他乐克治疗慢性充血性心力衰竭的临床疗效观察  

Clinical efficiency of β-blocker in chronic heartfailure disease

作　　者：张莉[1] 夏立志[1] 

机构地区：[1]哈尔滨市第3医院心内科,150066

出　　处：《航空航天医药》2006年第2期67-68,共2页Aerospace Medicine

摘　　要：目的:观察倍他乐克治疗慢性充血性心力衰竭的疗效及安全性。方法:选100例慢性充血性心力衰竭患者,随机单盲分成倍他乐克治疗组(治疗组)与常规治疗组(对照组)各50例。结果:治疗组均可耐受合适剂量的倍他乐克。6个月后治疗组及对照组左室射血分数均有所增加,但治疗组显著高于对照组(P<0.05);与对照组相比,6个月后治疗组左室收缩末期容积及舒张末期容积均显著缩小。治疗前后两组心功能分级均明显改善,但治疗组明显优于对照组(P<0.05)。结论:倍他乐克治疗慢性心力衰竭是安全、有效的。Objective： To investigate the efficancy and safety of β- blocker in chronic heart diease. Methods： One hundred chronic heart failure patients were divided randomly into observational group and control group for a follow - up period of six months. Each group has Fifty patients. Results：At the end of the study, LV ejection fraction（LVEF） increased in both groups, with the range of LVEF increasing more significantly in β-blocker group（P〈 0.05）;the left ventricular end - systolic volume index and the left ventricular end - diastolic volmne index were decreased obviously in - blocker group compared with those in control group after six months. The grade of heart fimtion were improved in both groups, with the range of increasing more significantly in β - blocker group（P〈 0.05）. Conclusion： β - blocker is a quite safe and efficient agent in chronic heartfailure disease.

关 键 词：倍他乐克 充血性心力衰竭 

分 类 号：R541.61[医药卫生—心血管疾病]